PCA3 in the detection and management of early prostate cancer
- PMID:23504524
- DOI: 10.1007/s13277-013-0739-6
PCA3 in the detection and management of early prostate cancer
Abstract
Although widely used, the value of prostate-specific antigen (PSA) in the detection of prostate cancer is controversial. The percentage of free PSA increases the specificity of PSA, but results are not enough. Prostate cancer gene 3 (PCA3) has been proposed as an option that may complement these markers in the detection and management of early prostate cancer. Our aim has been to review the value of PCA3 as tumor marker. The available results suggest that PCA3 is particularly useful to select in which patients the biopsy should be repeated when the first biopsy was negative. However, some points should be specified with further studies, including the most appropriate PCA3 cutoff level and the significance of a high PCA3 score in patients with negative biopsy. False-negative results are also a conflictive point in the use of PCA3, because prostate cancer, including aggressive tumors, may be present in patients with a low PCA3 score. Probably, a proper interpretation of this test requires its management together with other tests, through multivariate models for the detection of prostate cancer. On the other hand, several studies showed the relation between PCA3 score and Gleason score, and also the utility of PCA3 to select patients for active surveillance. To summarize, the available studies show the utility of PCA3 in the detection and management of early prostate cancer, although some aspects referred to its use need to be retested after further studies to confirm the actual value and the limitations of this test.
Similar articles
- Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O.Cornu JN, et al.Prostate. 2013 Feb 15;73(3):242-9. doi: 10.1002/pros.22563. Epub 2012 Jul 20.Prostate. 2013.PMID:22821767
- PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience.Merola R, Tomao L, Antenucci A, Sperduti I, Sentinelli S, Masi S, Mandoj C, Orlandi G, Papalia R, Guaglianone S, Costantini M, Cusumano G, Cigliana G, Ascenzi P, Gallucci M, Conti L.Merola R, et al.J Exp Clin Cancer Res. 2015 Feb 6;34(1):15. doi: 10.1186/s13046-015-0127-8.J Exp Clin Cancer Res. 2015.PMID:25651917Free PMC article.
- PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.Ramos CG, Valdevenito R, Vergara I, Anabalon P, Sanchez C, Fulla J.Ramos CG, et al.Urol Oncol. 2013 Nov;31(8):1522-6. doi: 10.1016/j.urolonc.2012.05.002. Epub 2012 Jun 9.Urol Oncol. 2013.PMID:22687565
- Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H.Auprich M, et al.Eur Urol. 2011 Nov;60(5):1045-54. doi: 10.1016/j.eururo.2011.08.003. Epub 2011 Aug 25.Eur Urol. 2011.PMID:21871709Review.
- Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer.Bradley LA, Palomaki GE, Gutman S, Samson D, Aronson N.Bradley LA, et al.J Urol. 2013 Aug;190(2):389-98. doi: 10.1016/j.juro.2013.02.005. Epub 2013 Mar 29.J Urol. 2013.PMID:23545099Review.
Cited by
- Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy.Wang FB, Chen R, Ren SC, Shi XL, Zhu YS, Zhang W, Jing TL, Zhang C, Gao X, Hou JG, Xu CL, Sun YH.Wang FB, et al.Asian J Androl. 2017 Mar-Apr;19(2):238-243. doi: 10.4103/1008-682X.167715.Asian J Androl. 2017.PMID:26780868Free PMC article.
- Clinical significance of NUCB2 mRNA expression in prostate cancer.Zhang H, Qi C, Li L, Luo F, Xu Y.Zhang H, et al.J Exp Clin Cancer Res. 2013 Aug 16;32(1):56. doi: 10.1186/1756-9966-32-56.J Exp Clin Cancer Res. 2013.PMID:23958433Free PMC article.
- CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.Kadry MO, Abdel-Megeed RM.Kadry MO, et al.PLoS One. 2024 May 9;19(5):e0302264. doi: 10.1371/journal.pone.0302264. eCollection 2024.PLoS One. 2024.PMID:38723038Free PMC article.
- Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.Merdan S, Tomlins SA, Barnett CL, Morgan TM, Montie JE, Wei JT, Denton BT.Merdan S, et al.Cancer. 2015 Nov 15;121(22):4071-9. doi: 10.1002/cncr.29611. Epub 2015 Aug 17.Cancer. 2015.PMID:26280815Free PMC article.
- Long Non-Coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers.Gao N, Li Y, Li J, Gao Z, Yang Z, Li Y, Liu H, Fan T.Gao N, et al.Front Oncol. 2020 Dec 18;10:598817. doi: 10.3389/fonc.2020.598817. eCollection 2020.Front Oncol. 2020.PMID:33392092Free PMC article.Review.
References
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous